Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
暂无分享,去创建一个
L. Leng | R. Bucala | D. Betteridge | K. Tan | S. Shiu | W. Chow | S. Shiu | Kcb Tan | Wing-Sun Chow
[1] V. Tesar,et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] H. Kaneto,et al. Endogenous secretory receptor for advanced glycation end product levels are inversely associated with HbA1c in type 2 diabetic patients. , 2006, Diabetes care.
[3] S. Fukumoto,et al. Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[4] H. Kaneto,et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. , 2005, Diabetes care.
[5] A. D'Angelo,et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.
[6] S. Jacqueminet,et al. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. , 2005, Clinical chemistry.
[7] D. Stern,et al. Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.
[8] Merlin C. Thomas,et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[9] A. D'Angelo,et al. Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[10] A. Schmidt,et al. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[11] J. Enghild,et al. Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)* , 2004, Journal of Biological Chemistry.
[12] Jeon-Soo Shin,et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.
[13] P. Rogalla,et al. Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.
[14] V. D’Agati,et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.
[15] S. Takasawa,et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.
[16] A. Schmidt,et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.
[17] R. Bucala,et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.
[18] R. Bucala,et al. Endothelial dysfunction and advanced glycation end products in type 2 diabetes mellitus , 2002 .
[19] T. Kislinger,et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.
[20] S. Takasawa,et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.
[21] A. Barden,et al. Advanced Glycation End Products: A Review , 2013 .
[22] Hiroshi Yamamoto,et al. The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[23] K. Kawasaki,et al. Roles of the AGE‐RAGE System in Vascular Injury in Diabetes a , 2000, Annals of the New York Academy of Sciences.
[24] H. Yamamoto,et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. , 2000, The Journal of biological chemistry.
[25] R. Bucala,et al. Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. , 2000, Bioconjugate chemistry.
[26] A. Schmidt,et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.
[27] J. Clausen,et al. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. , 1998, Diabetes care.
[28] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[29] Alan W. Stitt,et al. Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs , 1997, Molecular medicine.
[30] M. Cooper,et al. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury , 1997, Diabetologia.
[31] K. Gerbitz,et al. Possible Significance of Advanced Glycation End Products in Serum in End-Stage Renal Disease and in Late Complications of Diabetes , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.
[32] P. Guillausseau,et al. Rapid Publication , 1971, Nature.
[33] G. Otto,et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.
[34] Y. Zou,et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.
[35] Cockcroft Dw,et al. Prediction of Creatinine Clearance from Serum Creatinine , 1976 .